vs
Definitive Healthcare Corp.（DH）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
Definitive Healthcare Corp.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.7倍（$61.5M vs $35.5M），Definitive Healthcare Corp.净利率更高（-15.1% vs -304.2%，领先289.1%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs -1.2%），Definitive Healthcare Corp.自由现金流更多（$-1.7M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs -1.5%）
该企业是一家美国公司，主打非处方医疗健康产品与家居清洁产品的营销和分销。公司于1996年由美德泰产品公司、威望品牌国际与斯皮克Span公司合并成立，总部设在纽约塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
DH vs RXRX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $61.5M | $35.5M |
| 净利润 | $-9.3M | $-108.1M |
| 毛利率 | 76.2% | 59.8% |
| 营业利润率 | -43.3% | -304.8% |
| 净利率 | -15.1% | -304.2% |
| 营收同比 | -1.2% | 681.7% |
| 净利润同比 | 84.2% | 39.6% |
| 每股收益（稀释后） | $-0.14 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $61.5M | $35.5M | ||
| Q3 25 | $60.0M | $5.2M | ||
| Q2 25 | $60.8M | $19.2M | ||
| Q1 25 | $59.2M | $14.7M | ||
| Q4 24 | $62.3M | $4.5M | ||
| Q3 24 | $62.7M | $26.1M | ||
| Q2 24 | $63.7M | $14.4M | ||
| Q1 24 | $63.5M | $13.8M |
| Q4 25 | $-9.3M | $-108.1M | ||
| Q3 25 | $-14.8M | $-162.3M | ||
| Q2 25 | $-7.6M | $-171.9M | ||
| Q1 25 | $-107.2M | $-202.5M | ||
| Q4 24 | $-59.1M | $-178.9M | ||
| Q3 24 | $-130.9M | $-95.8M | ||
| Q2 24 | $-213.6M | $-97.5M | ||
| Q1 24 | $-9.5M | $-91.4M |
| Q4 25 | 76.2% | 59.8% | ||
| Q3 25 | 76.6% | -183.8% | ||
| Q2 25 | 76.7% | -4.9% | ||
| Q1 25 | 73.9% | -48.0% | ||
| Q4 24 | 76.4% | -181.4% | ||
| Q3 24 | 78.2% | 53.7% | ||
| Q2 24 | 79.2% | 36.2% | ||
| Q1 24 | 79.4% | 19.1% |
| Q4 25 | -43.3% | -304.8% | ||
| Q3 25 | -14.5% | -3327.6% | ||
| Q2 25 | -6.9% | -916.8% | ||
| Q1 25 | -312.2% | -1297.9% | ||
| Q4 24 | -159.8% | -4042.4% | ||
| Q3 24 | -359.5% | -377.1% | ||
| Q2 24 | -579.9% | -697.4% | ||
| Q1 24 | -25.6% | -698.4% |
| Q4 25 | -15.1% | -304.2% | ||
| Q3 25 | -24.7% | -3135.3% | ||
| Q2 25 | -12.4% | -894.2% | ||
| Q1 25 | -181.2% | -1373.3% | ||
| Q4 24 | -94.8% | -3935.5% | ||
| Q3 24 | -208.8% | -367.5% | ||
| Q2 24 | -335.2% | -676.6% | ||
| Q1 24 | -15.0% | -662.4% |
| Q4 25 | $-0.14 | $-0.17 | ||
| Q3 25 | $-0.14 | $-0.36 | ||
| Q2 25 | $-0.07 | $-0.41 | ||
| Q1 25 | $-0.95 | $-0.50 | ||
| Q4 24 | $-0.53 | $-0.56 | ||
| Q3 24 | $-1.12 | $-0.34 | ||
| Q2 24 | $-1.81 | $-0.40 | ||
| Q1 24 | $-0.08 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.9M | $743.3M |
| 总债务越低越好 | $156.1M | $9.6M |
| 股东权益账面价值 | $379.0M | $1.1B |
| 总资产 | $735.5M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.41× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | $180.9M | $743.3M | ||
| Q3 25 | $185.9M | $659.8M | ||
| Q2 25 | $184.2M | $525.1M | ||
| Q1 25 | $200.7M | $500.5M | ||
| Q4 24 | $290.2M | $594.4M | ||
| Q3 24 | $305.4M | $427.6M | ||
| Q2 24 | $296.5M | $474.3M | ||
| Q1 24 | $295.2M | $296.3M |
| Q4 25 | $156.1M | $9.6M | ||
| Q3 25 | $158.2M | $11.9M | ||
| Q2 25 | $160.3M | $14.2M | ||
| Q1 25 | $162.4M | $16.4M | ||
| Q4 24 | $229.4M | $19.0M | ||
| Q3 24 | $232.7M | $20.5M | ||
| Q2 24 | $236.0M | $22.9M | ||
| Q1 24 | $239.3M | — |
| Q4 25 | $379.0M | $1.1B | ||
| Q3 25 | $389.7M | $1.0B | ||
| Q2 25 | $411.2M | $919.1M | ||
| Q1 25 | $435.9M | $933.9M | ||
| Q4 24 | $607.2M | $1.0B | ||
| Q3 24 | $695.6M | $524.6M | ||
| Q2 24 | $886.3M | $584.4M | ||
| Q1 24 | $1.2B | $401.2M |
| Q4 25 | $735.5M | $1.5B | ||
| Q3 25 | $755.5M | $1.4B | ||
| Q2 25 | $770.1M | $1.3B | ||
| Q1 25 | $808.7M | $1.3B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $1.2B | $726.5M | ||
| Q2 24 | $1.4B | $775.9M | ||
| Q1 24 | $1.8B | $557.8M |
| Q4 25 | 0.41× | 0.01× | ||
| Q3 25 | 0.41× | 0.01× | ||
| Q2 25 | 0.39× | 0.02× | ||
| Q1 25 | 0.37× | 0.02× | ||
| Q4 24 | 0.38× | 0.02× | ||
| Q3 24 | 0.33× | 0.04× | ||
| Q2 24 | 0.27× | 0.04× | ||
| Q1 24 | 0.20× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.7M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $-1.7M | $-47.3M |
| 自由现金流率自由现金流/营收 | -2.8% | -133.1% |
| 资本支出强度资本支出/营收 | 7.2% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $37.1M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | $2.7M | $-46.1M | ||
| Q3 25 | $15.7M | $-117.4M | ||
| Q2 25 | $9.3M | $-76.4M | ||
| Q1 25 | $26.1M | $-132.0M | ||
| Q4 24 | $8.1M | $-115.4M | ||
| Q3 24 | $19.4M | $-59.2M | ||
| Q2 24 | $14.0M | $-82.2M | ||
| Q1 24 | $16.6M | $-102.3M |
| Q4 25 | $-1.7M | $-47.3M | ||
| Q3 25 | $13.4M | $-117.6M | ||
| Q2 25 | $7.0M | $-79.6M | ||
| Q1 25 | $18.4M | $-133.8M | ||
| Q4 24 | $-2.8M | $-116.7M | ||
| Q3 24 | $18.7M | $-63.8M | ||
| Q2 24 | $13.6M | $-83.4M | ||
| Q1 24 | $16.3M | $-109.0M |
| Q4 25 | -2.8% | -133.1% | ||
| Q3 25 | 22.3% | -2272.5% | ||
| Q2 25 | 11.5% | -413.9% | ||
| Q1 25 | 31.0% | -907.4% | ||
| Q4 24 | -4.4% | -2567.7% | ||
| Q3 24 | 29.8% | -244.6% | ||
| Q2 24 | 21.4% | -578.5% | ||
| Q1 24 | 25.7% | -789.9% |
| Q4 25 | 7.2% | 3.5% | ||
| Q3 25 | 3.8% | 4.7% | ||
| Q2 25 | 3.8% | 16.4% | ||
| Q1 25 | 13.0% | 12.4% | ||
| Q4 24 | 17.5% | 28.6% | ||
| Q3 24 | 1.2% | 17.5% | ||
| Q2 24 | 0.6% | 8.2% | ||
| Q1 24 | 0.4% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DH
| Subscription Services | $58.5M | 95% |
| Professional Services | $3.0M | 5% |
RXRX
暂无分部数据
